Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

Connect With My Medical Science Liaison

Chat Live

Available Monday - Friday 9AM - 4:30PM ET

Call Me Now

Available Monday - Friday 9AM - 7:30PM ET

Email Your Inquiry

Call 1-800-JANSSEN

Available Monday - Friday 9AM - 8PM ET

Live Video

Available Monday - Friday 9AM - 4:30PM ET